Diagnoses, Outcomes, and Chronicity Predictors of Patients with Secondary Immune Thrombocytopenia: Ten-Year Data from a Hematology Referral Center.
暂无分享,去创建一个
D. Gómez-Almaguer | J. Jaime-Pérez | Eugenia M. Ramos-Dávila | R. A. Jiménez-Castillo | Patrizia E Aguilar-Calderón
[1] Y. Kanakura,et al. Reevaluation of platelet function in chronic immune thrombocytopenia: impacts of platelet size, platelet‐associated anti‐αIIbβ3 antibodies and thrombopoietin receptor agonists , 2020, British journal of haematology.
[2] H. Al‐Samkari,et al. A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. , 2020, Blood advances.
[3] J. Bussel,et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. , 2019, Blood advances.
[4] D. Gómez-Almaguer,et al. Eltrombopag, low‐dose rituximab, and dexamethasone combination as frontline treatment of newly diagnosed immune thrombocytopaenia , 2019, British journal of haematology.
[5] D. Gómez-Almaguer,et al. Eltrombopag-based combination treatment for immune thrombocytopenia , 2018, Therapeutic advances in hematology.
[6] D. Gómez-Almaguer,et al. Evans syndrome: clinical perspectives, biological insights and treatment modalities , 2018, Journal of blood medicine.
[7] D. Gómez-Almaguer,et al. Contributions of a regional approach to document hematologic disease in Mexico: a 10-year experience in an open population , 2018, Hematology.
[8] J. González-Porras,et al. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice , 2017, British journal of haematology.
[9] S. Sultan,et al. Primary versus secondary immune thrombocytopenia in adults; a comparative analysis of clinical and laboratory attributes in newly diagnosed patients in Southern Pakistan. , 2016, The Medical journal of Malaysia.
[10] L. Abenhaim,et al. Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome , 2016, Haematologica.
[11] B. Chong,et al. Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro , 2015, Haematologica.
[12] Y. Shoenfeld,et al. Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases , 2014, Immunologic research.
[13] C. M. Murillo,et al. Trombocitopenia inmune primaria (TIP) del adulto en México: características nacionales y su relación con la literatura internacional , 2014 .
[14] J. Freedman,et al. Cellular immune dysfunction in immune thrombocytopenia (ITP) , 2013, British journal of haematology.
[15] M. Nørgaard,et al. Risk and prognosis of adult primary immune thrombocytopenia , 2012, Expert review of hematology.
[16] H. Tamary,et al. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group , 2011, Haematologica.
[17] E. L. Luning Prak,et al. The ITP syndrome: pathogenic and clinical diversity. , 2009, Blood.
[18] J. George,et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.
[19] J. Bussel. Therapeutic approaches to secondary immune thrombocytopenic purpura. , 2009, Seminars in hematology.
[20] G. Ruiz-Argüelles,et al. Helicobacter pylori infection and thrombocytopenia: a single-institution experience in Mexico. , 2007, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.
[21] R. Mcmillan. Immune thrombocytopenia. , 1983, Clinics in haematology.